The capital raise was well-telegraphed after positive Phase 3 data, but the 5.6% discount and 15.6% dilution create near-term overhang. Watch for the NDA resubmission timeline and FDA acceptance by end of 2026; the stock may trade range-bound until the regulatory decision in mid-2027. The 45-day lock-up expiration in early December 2026 could add further selling pressure.
Price Chart
Executive Summary
Disc Medicine priced a $450M public offering of 6,000,000 shares at $75.00 per share, a 5.6% discount to the prior close of $79.48. The offering follows positive Phase 3 APOLLO data for bitopertin announced on October 19, 2026. Net proceeds of ~$422.4M will extend cash runway into 2030, funding clinical development and potential commercialization of bitopertin. The 15.6% dilution is significant but the capital raise was expected given the upcoming NDA resubmission and commercial buildout.
Key Facts
- Offering of 6,000,000 shares at $75.00 per share, raising $450M gross / ~$422.4M net
- 5.6% discount to October 20, 2026 closing price of $79.48
- Underwriters have 30-day option for additional 900,000 shares
- Pro forma shares outstanding increase from 38,345,666 to 44,345,666 (15.6% dilution)
- Preliminary cash balance of ~$682.8M as of September 30, 2026; pro forma cash extends runway into 2030
- Positive Phase 3 APOLLO topline results for bitopertin announced October 19, 2026; NDA resubmission planned by end of 2026
- 45-day lock-up agreements for directors and executive officers
Financial Impact
15.6% dilution from 6M new shares; $422.4M net proceeds extend cash runway from 2029 to 2030
Risk Factors
- 15.6% immediate dilution to existing shareholders
- Potential for additional selling pressure when 45-day lock-up expires
- FDA decision on bitopertin NDA not expected until mid-2027, creating binary risk
- Up to $189.9M still available under at-the-market offering program
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-427982 |
| Document: d190758dexfilingfees.htm | 0001193125-26-427982 |
| Document: 0001193125-26-427982-index-headers.html | 0001193125-26-427982 |
| Document: 0001193125-26-427982-index.html | 0001193125-26-427982 |
| Document: 0001193125-26-427982.txt | 0001193125-26-427982 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D/A | — | awaiting T+20 | — | — |
Oct 22, 2026 4d ago | 8-K | $74.51 | awaiting T+20 | — | $74.51 (−0.00%) |
Oct 21, 2026 5d ago | 424B5 | $75.03 | awaiting T+20 | — | $74.51 (+0.69%) |
Oct 21, 2026 5d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 21, 2026 5d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 21, 2026 5d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 20, 2026 6d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 20, 2026 6d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 20, 2026 6d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 19, 2026 7d ago | 424B5 | $79.48 | awaiting T+20 | — | $74.51 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers